Havas moves into healthcare biotech with Noonan acquisition

NEW YORK: Havas Advertising has snapped up the US' largest

independent healthcare PR firm, Noonan/Russo Communications, for an

undisclosed figure.



The agency, with worldwide revenues of $14 million, specializes

in healthcare and biotech PR. It will operate independently within

Havas' diversified agencies group, which is comprised of 50 specialized

agencies.



"Noonan/Russo will fit in very well with Magnet and Abernathy MacGregor,

which we also recently acquired," said Simon Gillham, Havas' VP of

communications.



"The interesting thing about Noonan/Russo is it goes right across the

range in healthcare PR, from products to IR."



Susan Noonan, the firm's president and COO, said she wants the agency to

"build a much larger international footprint." Biotech is currently one

of the strongest parts of the firm's global business.



"Havas has a very strong respect for the entrepreneur," she said. "We

are excited to grow within the network, but still have autonomy in our

brand."



Noonan/Russo employs 200 people in three offices: New York, London, and

San Francisco. Noonan indicated that more staff will be added as a

result of the deal. The agency's clients include Genencor, Aventis,

Serono, DeCODE Genetics, and Myriad Genetics.



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.